Evotec Investor Presentation Deck

>9% T. Rowe Price Group evotec < 10% Novo Holdings A/S 2 68% Free float PAGE 39 52 week high/low: € 45.70/€ 21.12 Strong team and shareholders supporting sustainable growth Management & shareholder structure¹) 2 ~ 7% Mubadala Investment Company < 5% Roland Oetker/ROI Number of shares: 177.0 m Listings: Frankfurt Stock Exchange (MDAX, TecDAX), Ticker: EVT NASDAQ Global Select Market (ADS), Ticker: EVO ~1% Management 1) Rounding differences may occur Management Board • Werner Lanthaler (CEO) Long-time experience in Pharma & biotech • Cord Dohrmann (CSO) Long-time experience in drug discovery • Matthias Evers (CBO) Long-time experience in business development, technology and strategy ● Craig Johnstone (COO) Strong drug discovery and commercial track record • Enno Spillner (CFO) Long-time experience in finance & biotech Supervisory Board • Iris Löw-Friedrich UCB • Camilla Macapili Languille Mubadala Investment Co. • Mario Polywka Ex-Evotec • Roland Sackers QIAGEN • Elaine Sullivan Ex-Lilly • Constanze Ulmer-Eilfort PSP Munich

View entire presentation